Search This Blog

Friday, November 22, 2019

Agilent on watch after positive EU drug development

Agilent Technologies (NYSE:A) announces that its PD-L1 IHC 22C3 pharmDx assay is now labeled for use in HNSCC in the European Union.
The company says PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying HNSCC patients in Europe for treatment with Keytruda.
Source: Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)